{
  "id": 10876788,
  "title": "Takeda's Zasocitinib Shows Superior Skin Clearance In Phase 3 Psoriasis Trial",
  "url": "https://urgent.news/2026/09/30/takedas-zasocitinib-shows-superior-skin-clearance-in-phase-3",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-30T06:03:53.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/takedas-zasocitinib-shows-superior-skin-clearance-phase-3-psoriasis-trial"
  },
  "original_language": "en",
  "account": null,
  "summary": "(RTTNews) - Takeda Pharmaceutical Company Ltd. (TAK,4502.T) announced new data from three Phase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279) in adults with moderate-to-severe plaque psoriasis.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Financial Post",
        "title": "Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill",
        "url": "https://urgent.news/2026/09/30/zasocitinib-delivered-superior-efficacy-versus-deucravacitinib-in-new",
        "published": "2026-09-30T05:04:03.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}